Abstract
Background Suicide is a leading cause of death in adolescents worldwide. Previous research findings suggest that suicidal adolescents with depression have pathophysiological dorsolateral prefrontal cortex (DLPFC) deficits in γ-aminobutyric acid neurotransmission. Interventions with transcranial magnetic stimulation (TMS) directly address these underlying pathophysiological deficits in the prefrontal cortex. Theta burst stimulation (TBS) is newer dosing approach for TMS. Accelerated TBS (aTBS) involves administering multiple sessions of TMS daily as this dosing may be more efficient, tolerable, and rapid acting than standard TMS.
Methods: This is a randomized, double-blind, sham-controlled trial of sequential bilateral aTBS in adolescents with MDD and suicidal ideation. Three sessions are administered daily for 10 days. During each session, continuous TBS is administered first to the right DPFC, in which 1,800 pulses are delivered continuously over 120 seconds. Then intermittent TBS is applied to the left DPFC, in which 1,800 pulses are delivered in 2-second bursts and repeated every 10 seconds for 570 seconds. The TBS parameters were adopted from prior research, with 3-pulse, 50-Hz bursts given every 200 ms (at 5 Hz) with an intensity of 80% active motor threshold. The comparison group will receive 3 daily sessions of bilateral sham TBS treatment for 10 days. All participants will receive the standard of care for patients with depression and suicidal ideation including daily psychotherapeutic skill sessions. Long-interval intracortical inhibition (LICI) biomarkers will be measured before and after treatment. Exploratory measures will be collected with TMS and electroencephalography for biomarker development.
Discussion This is the first known randomized controlled trial to examine the efficacy of sequential bilateral aTBS for treating suicidal ideation in adolescents with MDD. Results from this study will also provide opportunities to further understand the neurophysiological and molecular mechanisms of suicidal ideation in adolescents.
Trial registration Investigational device exemption (IDE) Number: G200220, ClinicalTrials.gov (ID: NCT04701840). Registered August 6, 2020. https://clinicaltrials.gov/ct2/show/NCT04502758?term=NCT04701840&draw=2&rank=1
Competing Interest Statement
Dr Croarkin has received research grant support from Neuronetics Inc, NeoSync Inc, and Pfizer Inc. He has received in-kind support (equipment, supplies, and genotyping) for research studies from Assurex Health Inc, Neuronetics Inc, and MagVenture Inc. He has consulted for Engrail Therapeutics Inc, Myriad Neuroscience, Procter & Gamble, and Sunovion. Dr Vande Voort has received in-kind support (supplies and genotyping) from Assurex Health Inc. The other authors declare that they have no competing interests.
Clinical Trial
ClinicalTrials.gov (ID: NCT04701840) https://clinicaltrials.gov/ct2/show/NCT04502758?term=NCT04701840&draw=2&rank=1
Funding Statement
This project is supported by Grant Number 1 R01 MH124655-01 from the NIMH, National Institutes of Health (NIH) (awarded to PEC), and by Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS) (awarded to PEC). The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.The content of this protocol and publication is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This protocol is approved by the Mayo Clinic IRB (20-009630), NIMH DSMB, and FDA Investigational device exemption (IDE) Number: G200220
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.
- Abbreviations
- AE
- adverse event
- aTBS
- accelerated theta burst stimulation
- CDRS-R
- Children’s Depression Rating Scale Revised
- CRF
- case report form
- C-SSRS
- Columbia–Suicide Severity Rating Scale
- DPFC
- dorsolateral prefrontal cortex
- DSMB
- Data and Safety Monitoring Board
- EEG
- electroencephalography
- EMG
- electromyography
- FDA
- US Food and Drug Administration
- GABA
- γ-aminobutyric acid
- GEE
- generalized estimating equation
- HIPAA
- Health Insurance Portability and Accountability Act
- IDE
- investigational device exemption
- IRB
- institutional review board
- LICI
- long-interval intracortical inhibition
- LICI-100
- LICI at an interstimulus interval of 100 ms
- MDD
- major depressive disorder
- MINI-KID
- Mini-International Neuropsychiatric Interview for Children and Adolescents
- MNAR
- missing not at random
- MT
- motor threshold
- N45
- 45 ms after stimulation
- N100
- 100 ms after stimulation
- NDA
- US National Institute of Mental Health Data Archive
- NIH
- US National Institutes of Health
- NIMH
- US National Institute of Mental Health
- OR
- odds ratio
- PHI
- protected health information
- PI
- principal investigator
- SAE
- serious adverse event
- TBS
- theta burst stimulation
- TMS
- transcranial magnetic stimulation
- UADE
- unanticipated adverse device effect
